CHECKPOINT INHIBITOR VACCINES
Virion Therapeutics, LLC
Mark For: CHECKPOINT INHIBITOR VACCINES™ trademark registration is intended to cover the categories of
| Research |
OneLook
Acronym Finder
|
| Serial Number | 88162144 |
| Mark Literal Elements | CHECKPOINT INHIBITOR VACCINES |
| Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
| Mark Type | SERVICE MARK |
| Register | PRINCIPAL |
| Current Location | TMO LAW OFFICE 113 - EXAMINING ATTORNEY ASSIGNED 2019-09-02 |
| Basis | 1(a) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | Yes |
| Current Use | Yes |
| Intent To Use | No |
| Filed ITU | No |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Attorney Name | Elizabeth Oliner |
| Law Office Assigned | M40 |
| Employee Name | FOX III, LYAL L |
Timeline
| 2018-01-02 | Date of First Use |
| 2018-02-01 | Date of Use In Commerce |
| 2018-10-19 | Application Filed |
| 2019-08-06 | Abandon |
| 2019-09-02 | Location: TMO LAW OFFICE 113 - EXAMINING ATTORNEY ASSIGNED |
| 2019-09-02 | Status: Abandoned because the applicant failed to respond or filed a late response to an Office action. To view all documents in this fi |
| 2019-09-02 | Status: Dead/Abandoned |
| 2019-09-03 | Transaction Date |
Trademark Parties (Applicants & Owners)
| Party: |  Virion Therapeutics, LLC |
| Address | 7 Creek Bend Ct. Newark, DELAWARE UNITED STATES 19711 |
| Legal Entity Type | Limited Liability Company |
| Legal Entity State | DELAWARE |
Documents
 Drawing | JPEG | 2018-10-19 |
| Specimen | JPEG | 2018-10-19 |
 TEAS Plus New Application | MULTI | 2018-10-19 |
| XSearch Search Summary | XML | 2019-01-29 |
| Offc Action Outgoing | MULTI | 2019-02-04 |
| Notice of Abandonment | APPLICATION/XML | 2019-09-03 |
Attorney of Record
Good, Services, and Codes
(ABANDONED)
IC 042. US 100 101. G & S: Biomedical research services; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific research; Scientific research in the field of vaccines. FIRST USE: 20180102. FIRST USE IN COMMERCE: 20180200
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0421 | Biomedical research services; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific research; Scientific research in the field of vaccines |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | 2019-09-03 | |
| ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | 2019-09-02 | |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2019-02-04 | 6325 |
| NON-FINAL ACTION WRITTEN | 2019-02-04 | 93928 |
| NON-FINAL ACTION E-MAILED | 2019-02-04 | 6325 |
| ASSIGNED TO EXAMINER | 2019-01-29 | 93928 |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-11-01 | |
| NEW APPLICATION ENTERED IN TRAM | 2018-10-23 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 